Ramin Khoramnia (University Eye Clinic Heidelberg, Heidelberg, Germany) discusses imitations of current treatment options for neovascular age-related macular degeneration, gives an overview of faricimab, its dosing regimen and its mechanism of action and discusses the major efficacy and safety findings of the STAIRWAY study, which were presented at WOC 2020.
1. What are the limitations of current treatment options for neovascular age-related macular degeneration? (0:05)
2. Could you give us an overview of faricimab, its dosing regimen and its mechanism of action? (1:07)
3. What were the aims and design of the STAIRWAY study? (2:07)
4. What were the major efficacy and safety findings of this study? (2:54)
5. What is the potential for combining faricimab with angiopoietin-2 and vascular endothelial growth factor inhibitors and what future studies are planned? (3:33)
Disclosures: Ramin Khoramnia has received grant support from: Alimera, Bayer, Chengdu Kanghong, Novartis, and Roche; travel support from: Alimera, Allergan, Bayer, Novartis, and Roche; and lecture fees from: Alimera, Allergan, Bayer, Novartis, and Roche.
touchOPHTHALMOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Commissioned, edited and funded by Touch Medical Media
Published: 31 July 2020
Share this Video
Related Videos In Macular Degeneration
Usha Chakravarthy, EURETINA 2022: Persistent fluid in neovascular age-related macular degeneration
The Archway study (NCT03677934) was a phase 3, randomized, active treatment–controlled trial for the treatment of nAMD, conducted at 77 study locations in the United States. We caught up with Prof. Usha Chakravarthy (Queen’s University of Belfast, Belfast, Northern Ireland) to discuss the causes of persistent fluid in neovascular age-related macular degeneration and the impact […]
Anat Loewenstein, EURETINA 2022: Home Monitoring for Age-related Macular Degeneration
It was a pleasure to interview Prof. Anat Loewenstein (Tel Aviv Medical Center, Tel Aviv, Israel) on her EURETINA presentation discussing the advantages of home monitoring of age-related macular degeneration, and the results of a study evaluating a new device for home monitoring. The abstract ‘Functional and anatomical options for home monitoring in the era […]
Katerina Prokopiou, ARVO 2022: Therapeutic potential of omega-3 fatty acids supplementation in dry age-related macular degeneration and Stargardt Disease
The clinical outcomes of the MADEOS trial (NCT03297515) is discussed in this touchOPHTHALMOLOGY interview with Dr Katerina Prokopiou (University of Nicosia Medical School, Engomi, Cyprus). Currently, there is no effective treatment available that stops progression or improves vision in patients with dry age-related macular degeneration or Stargardt disease, the MADEOS trial assesses the therapeutic potential of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!